- Home
- URGN vs BTX Comparison
URGN vs BTX Comparison
Compare URGN & BTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | URGN | BTX |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 922.1M | 770.3M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | URGN | BTX |
|---|---|---|
| Price | $18.87 | $6.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $29.29 | N/A |
| AVG Volume (30 Days) | ★ 665.3K | 613.2K |
| Earning Date | 05-11-2026 | 11-01-2025 |
| Dividend Yield | N/A | ★ 12.11% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,128,000.00 | N/A |
| Revenue This Year | $127.17 | N/A |
| Revenue Next Year | $73.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.42 | $5.10 |
| 52 Week High | $30.00 | $7.50 |
Technical Indicators
Market Signals| Indicator | URGN | BTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 54.22 |
| Support Level | $18.37 | $6.55 |
| Resistance Level | $20.44 | $6.91 |
| Average True Range (ATR) | 0.91 | 0.20 |
| MACD | 0.14 | 0.03 |
| Stochastic Oscillator | 80.51 | 79.05 |
Price Performance
Historical ComparisonAbout URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About BTX BlackRock Technology and Private Equity Term Trust
BlackRock Technology and Private Equity Term Trust is a closed-end management investment company. Its investment objectives are to provide total return and income through long-term capital appreciation.